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Context: Per- and polyfluoroalkyl substances (PFAS) are environmental chemicals linked to 
weight gain and type 2 diabetes.  
Objective: We examined the extent to which PFAS plasma concentrations during pregnancy 
were associated with postpartum anthropometry and biomarkers. 
Design, Patients, Measures: We studied women recruited between 1999-2002 in the Project 
Viva prospective cohort with pregnancy plasma concentrations of PFAS, including 
perfluorooctanesulfonic acid (PFOS), perfluorooctanoic acid (PFOA), and 2-(N-ethyl-
perfluorooctane sulfonamide) acetic acid (EtFOSAA). Three-year postpartum anthropometry 
measurements were available from 786-801 women, blood pressure from 761 women, and 
blood biomarkers from 450-454 women. We used multivariable regression to evaluate the 
association of log2-transformed PFAS with postpartum anthropometry, blood pressure, and 
blood biomarkers (leptin, adiponectin, sex hormone binding globulin [SHBG], hemoglobin 
A1c [HbA1c], interleukin-6 [IL-6], C-reactive protein [CRP]), adjusting for age, pre-
pregnancy BMI, marital status, race/ethnicity, education, income, smoking, parity, and 
breastfeeding history.   
Results: Pregnancy concentrations of certain PFAS were associated with greater adiposity 
(e.g., 0.4 cm [95%CI: -0.1, 0.9] greater waist circumference per doubling in EtFOSAA; 0.2 
cm [95%CI: -0.1, 0.5] greater mid-upper arm circumference per doubling in PFOA; 1.2 mm 
[95%CI: 0.1, 2.2] thicker sum of subscapular and triceps skinfolds per doubling in PFOS) and 
higher systolic blood pressure (e.g., 1.2 mm Hg [95%CI: 0.3, 2.2] per doubling in PFOS) at 
three years postpartum. Higher EtFOSAA concentrations were also associated with 10.8% 
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Conclusions: Pregnancy concentrations of EtFOSAA, PFOS, and PFOA were associated 
with adverse postpartum cardiometabolic markers. 
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Growing epidemiologic evidence suggests that pregnancy complications may indicate 
elevated long-term maternal cardiometabolic risk [1]. For example, gestational diabetes is strongly 
associated with a woman’s future risk of developing type 2 diabetes [2], and excessive gestational 
weight gain has been linked with greater postpartum weight retention and future weight gain [3]. 
Indeed, metabolic disruptions in pregnancy are associated with mothers’ postpartum cardiometabolic 
health in clinically measurable ways as soon as a few years after pregnancy. Cumulative incidence of 
type 2 diabetes increases most rapidly in the first 5 years after a gestational diabetes pregnancy, and 
the incidence of new pharmacologically-treated hypertension is highest in the first 4 years after a 
pregnancy complicated by preterm delivery, pre-eclampsia, or gestational diabetes [2 4]. Though 
research on pregnancy complications indicates that metabolic disruption in pregnancy is associated 
with long-term health risks, little research has examined whether exposures to other stressors in 
pregnancy, including chemical toxicant exposures, might be associated with postpartum 
cardiometabolic health.  
Per- and polyfluoroalkyl substances (PFAS) are endocrine disrupting chemicals that have 
been manufactured in the U.S. and worldwide since the 1950s [5]. They can be used in food 
packaging, cooking equipment, water- and stain-resistant fabric treatments, and firefighting foams [6-
8], and some have multi-year half-lives in humans [9]. U.S. adults are ubiquitously exposed to 
multiple PFAS, largely through consumption of contaminated food and water [10]. In pregnant 
populations, PFAS concentrations are positively associated with income [11-13]. Associations with 
race/ethnicity are inconsistent and vary across studies [11-13], possibly because drinking water 
contaminated by PFAS (e.g., industrial wastewater, airport runoff, military base runoff) is a major 
exposure source [8], and the relationship between demographic factors such as race and proximity to 
contaminated water varies from place to place [14]. Despite a voluntary U.S. phase-out of PFOS and 
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 Exposures to several PFAS have been linked to poorer cardiometabolic health in non-
pregnant adults, including weight gain, incident diabetes, and microvascular disease [17-20], 
potentially via activation by PFAS of PPAR-  and ER-  [21 22]. However, prior studies 
inconsistently link PFAS exposure and changes in blood biomarkers associated with incident 
cardiometabolic outcomes, such as leptin, adiponectin, sex hormone binding globulin (SHBG), 
hemoglobin A1c (HbA1c), interleukin-6 (IL-6), and C-reactive protein (CRP) [23-32]. Only two 
studies of PFAS and biomarkers in adults evaluated associations in pregnant populations (one null 
study of CRP and one study of IL-6 that reported positive associations), so possible effects of PFAS 
in this potentially sensitive window [33] are largely unknown [34 35]. To our knowledge, no study 
has assessed PFAS exposure in pregnancy and maternal cardiometabolic health in the years following 
pregnancy, a potentially sensitive window of metabolic disruption. 
In this study, we used a longitudinal pre-birth cohort to evaluate associations of plasma PFAS 
concentrations measured in pregnancy and maternal plasma biomarkers (leptin, adiponectin, SHBG, 
HbA1c, IL-6, CRP), blood pressure, and anthropometric measurements at three years postpartum. We 
hypothesized that higher pregnancy PFAS concentrations would be associated with a worse 
cardiometabolic profile: higher IL-6, CRP, HbA1c, and leptin; lower SHBG and adiponectin; and 
higher adiposity and blood pressure at three years postpartum. 
Methods 
Project Viva is a prospective pre-birth cohort of women recruited between 1999 and 2002 
during their first prenatal visit at Atrius Harvard Vanguard Medical Associates, a multi-specialty 
group practice in eastern Massachusetts [36]. Eligible women spoke English, were pregnant with a 
single fetus, were less than 22 weeks’ gestation, and planned to deliver in eastern Massachusetts. All 
participants provided written informed consent and the human subjects committee of Harvard Pilgrim 
Health Care approved all procedures. Participants completed multiple study visits, including during 
pregnancy, at delivery, and at three years postpartum, and completed interviews and questionnaires at 
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analysis to the first eligible pregnancy for each participant. We also excluded pregnancies without 
plasma PFAS measurements (n=472) and those with pre-pregnancy type 1 or type 2 diabetes (n=14), 
leaving an eligible population of 1614 participants at baseline.  
We collected blood samples in early pregnancy (median 9.7 weeks; range 4.8-21.4 weeks). 
We stored plasma in non-PFAS-containing cryovials in liquid nitrogen freezers at  -130°C until 
shipment to the CDC laboratory in 2014. At CDC, plasma was stored at or below −40°C until analysis 
in 2014. CDC staff quantified PFAS by on-line solid-phase extraction coupled with isotope dilution 
high-performance liquid chromatography–tandem mass spectrometry as described in detail before 
[37]. The analytical method was the same used to analyze PFAS concentrations in the 2011–2012 
Health and Nutrition Examination Survey (NHANES) cycle [38]. Repeated measurements of serum 
quality control pools, reflecting both inter- and intra-day variation, had coefficients of variation for 
the PFAS in this study of about 8-13% [38]. To ensure accuracy and reliability, the laboratory 
analyzed low and high-concentration quality control materials, analytical standards, and reagent and 
serum blanks along with the study samples; the laboratory successfully participated in external quality 
assessment schemes [37].The PFAS were: perfluorooctanoic acid (PFOA), perfluorooctane sulfonic 
acid (PFOS), perfluorononanoic acid (PFNA), perfluorohexane sulfonic acid (PFHxS), 
perfluorodecanoic acid (PFDA), 2-(N-ethyl-perfluorooctane sulfonamido) acetic acid (EtFOSAA), 
and 2-(N-methyl-perfluorooctane sulfonamido) acetic acid (MeFOSAA). PFOS and PFOA measures 
represented total PFOS and PFOA (sum of linear and branched isomers). Limits of detection (LOD) 
were 0.2 ng/mL for PFOS and 0.1 ng/mL for all other PFAS. All PFAS except PFDA were detected in 
over 98% of samples. We excluded PFDA from analysis because it was detected in only 45% of 
samples. For other PFAS, we imputed values below the LOD (<1% of samples) using LOD/√  [39]. 
The analysis of coded samples at the CDC laboratory did not constitute engagement in human 
subjects research.  
During in-person visits at three years postpartum, trained research assistants (RAs) measured 
adiposity, weight, height, and blood pressure. RAs measured subscapular skinfold thickness and 
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We added subscapular and triceps skinfold thickness measures to create a single skinfold thickness 
measure (SS+TR) for analysis [40]. RAs measured waist circumference and mid-upper arm 
circumference using a Lefkin woven tape and recorded measurements to the nearest 0.1 cm. RAs 
measured weight (participants removed their shoes but were otherwise fully clothed) using a Seca 
scale and recorded measurements to the nearest 0.1 kg. RAs measured height using a stadiometer and 
recorded measurements to the nearest 0.1 cm. We used RA-measured weight and height to calculate 
body mass index (BMI, weight [kg]/height[m
2
]).  
RAs measured diastolic and systolic blood pressure five consecutive times each using the 
participant’s right arm, with measurements 1 minute apart, using the Dinamap Pro100 or 
DinamapPro200 automated blood pressure recorder. We took the average of the last four 
measurements for analysis, discarding the first measurement [41]. For participants contributing fewer 
than five measurements (n=4 participants), we discarded the first measurement and calculated an 
average from the remaining measurements.  
Trained phlebotomists collected blood samples, and we froze the blood samples in non-
PFAS-containing cryovials in liquid nitrogen freezers at  -130°C within 24 hours of collection. The 
Boston Children’s Hospital Clinical Chemistry Laboratory measured HbA1c, adiponectin, leptin, 
CRP, SHBG, and IL-6 in the collected samples. Investigators in an earlier study measured these blood 
biomarkers to test the effects of lactation on postpartum diabetic risk factors; we used the same 
biomarker measurements here [42 43]. Measurement of blood biomarkers has been previously 
described [42 43]. Briefly, we quantified HbA1c using the Hitachi 917 analyzer (Roche Diagnostics) 
and quantified leptin and adiponectin using enzyme-linked immunosorbent assays (R&D Systems). 
We measured CRP using an immunoturbidimetric high-sensitivity assay on a Hitachi 911 analyzer 
(Roche Diagnostics) and reagents and calibrators from Denka Seiken. We measured SHBG using a 
competitive electrochemiluminescence immunoassay on the 2010 Elecsys autoanalyzer (Roche 
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Covariate data collection 
At recruitment, participants reported race/ethnicity, age, education, parity, marital status, 
household income, and smoking status. To calculate pre-pregnancy BMI, we used self-reported pre-
pregnancy weight and height. We estimated history of breastfeeding using parity and information 
about breastfeeding after the index pregnancy: we classified nulliparous women and women who did 
not breastfeed after the index pregnancy as having no history of breastfeeding, and we classified 
parous women who breastfed after the index pregnancy as having a history of breastfeeding [13]. We 
selected confounders using directed acyclic graphs and previous literature [11-13] and adjusted all 
models for age, continuous pre-pregnancy BMI, marital status (married/cohabitating versus not), 
race/ethnicity (black, white, or other), education (college graduate or more versus less than college 
graduate), household income (>$70,000 versus ≤$70,000), smoking (current, former, or never), parity 
(0, 1, or >1), and history of breastfeeding (ever versus never).  
 
Statistical analysis 
We log2-transformed PFAS plasma concentrations; effect estimates are presented per doubling of 
PFAS concentrations. We natural-log transformed blood biomarker levels measured in postpartum; 
effect estimates for these models are reported as percent difference in biomarker per doubling in 
PFAS. We used chained equations in SAS PROC MI to multiply impute missing baseline covariate 
values (12% of participants were missing any covariate) and breastfeeding in fifty datasets, using data 
from exposures, outcomes, and additional covariates (a full list of covariates used in imputations can 
be found in the Supplemental Material [44]). We chose to generate fifty imputations to ensure 
reproducibility of the estimates [36]. We combined the results from the fifty imputed datasets in the 
analysis.  
We evaluated the association between plasma PFAS concentrations and each 3-year 
postpartum biomarker and anthropometry measure using multivariable linear regression models. We 
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(n=192). Because of small amounts of missing data for some outcomes, sample sizes in fully adjusted 
models ranged from n=786 to n=801 for 3-year anthropometry models; we excluded women with pre-
pregnancy hypertension (n=73) from blood pressure models resulting in a sample size of n=761 for 
fully adjusted blood pressure models. Because only a subset of participants elected to give blood 
samples at three years postpartum, sample sizes ranged from n=450 to n=454 for blood biomarker 
models. To correct for non-random loss to follow-up associated with a post-baseline variable 
(gestational weight gain) resulting in potential selection bias, we used stabilized inverse probability of 
censoring weights (IPCW) [45], which upweighted individuals remaining in the population to take the 
place of those who were lost to follow-up, based on demographics and gestational weight gain. We 
calculated separate IPCW for each PFAS in each imputed dataset, and calculated denominators of the 
weights using all baseline confounders as well as total gestational weight gain (predictors of loss to 
follow-up). Analyses were performed using SAS 9.4 (SAS Institute Inc.).   
 
Sensitivity analyses 
To ensure that our results were not due to confounding by correlations among the PFAS, we 
additionally repeated all analyses including all PFAS in a single model to control for PFAS-PFAS 
confounding. To ensure that our results were not affected by length of time since the most recent 
pregnancy, we repeated the analysis excluding women who became pregnant again after the index 
pregnancy and before the time of the health outcome measurements. To test whether findings were 
modified by maternal age at baseline, we additionally stratified all models by maternal age (<35 years 
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Compared to women with PFAS measurements, women without PFAS measurements were slightly 
more likely to have a history of breastfeeding (45% versus 41%) and have a normal pre-pregnancy 
BMI (67% versus 61%), were more likely to be a race other than white (40% versus 32%), and were 
more likely to have enrolled in the study in 2001 or 2002 (instead of 1999 or 2000) (54% versus 
38%). They did not substantially differ from included women by age, parity, education, marital status, 
smoking status, or household income. Most participants included in our current analyses were aged 30 
or older at pregnancy, were white, had graduated from college, and had a household income greater 
than $70,000/year (Table 1, Supplemental Table S1 [44]). Imputations did not affect the distribution 
of covariates in the study population (Supplemental Table S2 [44]).  
Compared to those without anthropometry, blood pressure, or blood biomarker measurements 
at three years postpartum, the subset included in the analysis was more often over age 35 at 
pregnancy, white, and college graduates; and less often smoked in pregnancy. Spearman correlation 
coefficients between the six PFAS ranged from 0.18 to 0.74; most correlations were between 0.2 and 
0.5 (Supplemental Table S3 [44]). 
 
Anthropometry 
In the anthropometry sample, median BMI at three years postpartum was 24.9 kg/m
2
 (interquartile 
range: 22.0-28.7); approximately 50% of women had BMI ≥ 25 kg/m
2
 and approximately 20% of 
women had BMI ≥ 30kg/m
2
. Mean waist circumference was 87.0 cm (standard deviation (SD)= 12.8 
cm).  
Certain PFAS were associated with greater adiposity at three years postpartum, though some 
confidence intervals crossed the null (Figure 1; Supplemental Table S4 [44]). Participants had, on 
average, 0.3 kg/m
2
 (95% confidence interval [CI]: 0.0, 0.6) higher 3-year postpartum BMI per 
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waist circumference per doubling in pregnancy EtFOSAA concentrations, in fully adjusted models 
(which include pre-pregnancy BMI as a covariate). Applying these findings to the observed range of 
PFOA and EtFOSAA, those at the 75
th
 percentile of PFOA concentrations in pregnancy (7.6 ng/mL) 
would have on average 0.3 kg/m
2
 higher BMI at three years postpartum than those at the 25
th
 
percentile of pregnancy concentrations (4.0 ng/mL), and those at the 75
th
 percentile of pregnancy 
EtFOSAA concentrations (1.9 ng/mL) would have on average 0.6 cm larger waist circumference at 
three years postpartum than those at the 25
th
 percentile of EtFOSAA pregnancy concentrations (0.7 
ng/mL). PFOA, PFOS, and EtFOSAA were also associated with greater average mid-upper arm 
circumference, though confidence intervals crossed the null (0.2 cm [95%CI: -0.1, 0.4] higher per 
doubling in PFOS, 0.2 cm [95%CI: -0.1, 0.5] higher per doubling in PFOA, and 0.1 cm [95%CI: -0.0, 
0.3] higher per doubling in EtFOSAA); and greater SS+TR skinfold thicknesses (1.2 [95%CI: 0.1, 
2.2] mm higher per doubling in PFOS, 0.9 mm [95%CI: -0.3, 2.1] higher per doubling in PFOA, and 
0.6 mm [95%CI: -0.1, 1.4] higher per doubling in EtFOSAA), though confidence intervals crossed the 
null (Figure 1; Supplemental Table S4 [44]). PFHxS, PFNA, and MeFOSAA were not associated with 
measures of adiposity.  
 
Blood pressure 
In the blood pressure sample, mean systolic blood pressure was 108 mm Hg (SD = 11 mm 
Hg), and mean diastolic blood pressure was 66 mm Hg (SD= 8 mm Hg).  Six women (0.8%) had 
incident hypertension (defined as systolic blood pressure >140 or diastolic blood pressure >90 mmHg 
and no hypertension before the index pregnancy). Pregnancy plasma concentrations of PFOS, PFOA, 
and MeFOSAA were associated with greater systolic blood pressure at three years postpartum, though 
confidence intervals contained the null in some cases (Figure 2; Supplemental Table S4 [44]). Systolic 
blood pressure was 1.2 mm Hg (95%CI: 0.3, 2.2) higher per doubling of PFOS and 0.8 mm Hg 
(95%CI: -0.3, 1.8) higher per doubling of PFOA. Applying these findings to the observed range of 
PFOS, those at the 75
th
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on average 1.1 mm Hg higher systolic blood pressure at three years postpartum than those at the 25
th
 
percentile of PFOS pregnancy concentrations (18.2 ng/mL). No PFAS were associated with diastolic 
blood pressure. PFHxS and PFNA were not strongly associated with blood pressure at three years 
postpartum (Figure 2; Supplemental Table S4 [44]).  
 
Blood biomarkers (leptin, adiponectin, SHBG, HbA1c, IL-6, CRP) 
Certain PFAS were associated with concentrations of multiple blood biomarkers at three 
years postpartum (Figure 3; Supplemental Table S5 [44]). Pregnancy plasma concentrations of 
EtFOSAA and MeFOSAA were associated with greater 3-year postpartum IL-6 (10.8% [95%CI: 3.3, 
18.9] higher and 14.5% [95%CI: 5.7, 24.1] higher IL-6 per doubling in EtFOSAA and MeFOSAA, 
respectively). Each doubling in pregnancy PFHxS concentration was associated with 8.0% (95%CI: 
2.2, 14.0) greater SHBG, while each doubling in pregnancy EtFOSAA was associated with 6.1% 
(95%CI: 0.7, 11.2) lower SHBG at three years postpartum. Participants had on average 16.1% (95%: 
3.8, 26.9) lower 3-year postpartum CRP per doubling in pregnancy MeFOSAA and 5.3% (95%CI: 
0.3, 10.4) higher 3-year postpartum adiponectin per doubling in pregnancy PFHxS. No pregnancy 
PFAS concentrations were associated with leptin at three years postpartum. PFOS, PFOA, and PFNA 
were generally weakly associated with blood biomarkers of cardiometabolic disruption at three years 
postpartum (Figure 3; Supplemental Table S5 [44]).  
Secondary and sensitivity analyses 
When we repeated analyses with all PFAS in a single model, associations with each PFAS were 
generally consistent in both strength and direction with results from individual PFAS models 
(Supplemental Table S4, S5 [44]). Models that excluded all women who became pregnant after the 
index pregnancy were also in general similar to results from the main models (which excluded women 
pregnant within the last 6 months) (Supplemental Table S4, S5 [44]). We did not find strong evidence 
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PFOA with systolic blood pressure were stronger among women aged 35 years or older at pregnancy 
as compared to women younger than 35 (Supplemental Table S6, S7 [44]).  
 
Discussion 
We observed that plasma concentrations of several PFAS during early pregnancy were associated 
with poorer anthropometry, blood pressure, and blood biomarkers (leptin, adiponectin, SHBG, 
HbA1c, IL-6, CRP) measured three years postpartum, suggesting that greater PFAS exposures were 
associated with higher cardiometabolic risk. Specifically, EtFOSAA was associated with a higher-risk 
profile across both anthropometric measures (greater waist circumference, mid-upper arm 
circumference, and SS+TR skinfold thickness) and biomarkers (higher IL-6, HbA1c, and lower 
SHBG), though not all associations were statistically significant. PFOA was linked to higher-risk 
anthropometry such as greater mid-upper arm circumference and BMI, and both PFOS and PFOA 
were associated with greater SS+TR skinfold thickness and systolic blood pressure, though not all 
associations were statistically significant. To our knowledge, this is the first study to report that PFAS 
concentrations in pregnancy are associated with postpartum anthropometry, blood pressure, and blood 
biomarkers of cardiometabolic risk. 
Our findings linking certain PFAS to higher postpartum adiposity are consistent with a variety 
of previous studies in non-pregnant populations. For example, PFOS and PFOA have been associated 
with adiposity, weight gain [18 20] and type 2 diabetes [46]. Similarly, EtFOSAA was linked to 
prevalent microvascular disease in a non-pregnant U.S. population in the Diabetes Prevention 
Program Outcomes Study [17]. In prior work in this cohort, we also found that EtFOSAA is 
associated with higher gestational weight gain [47]. PFAS may be causing increased adiposity by 
activating PPAR  [21 22], which is expressed in adipose tissue and regulates adipocyte differentiation 
as well as fatty acid storage [48]. In addition to epidemiologic findings, evidence from in vitro studies, 
showing that PFAS exposure increases adipocyte cell number while reducing cell size and causes less 
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On the other hand, as far as we are aware, this is the first prospective study to report a positive 
association between PFAS plasma concentrations and systolic blood pressure. Some prior cross-
sectional studies have suggested a positive association of PFAS and blood pressure [20 51], though 
not all reported positive findings [52]. Several prospective studies in substantially older, non-pregnant 
populations reported null associations of PFAS and hypertension [46 53], though one of these studies 
reported positive associations of cumulative PFOA exposure and hypertension among women aged 
20-39 only (similar to the demographics of the Viva population) [53]. One recent longitudinal trial in 
a population at risk of type 2 diabetes reported inverse associations of MeFOSAA and PFOS with 
systolic blood pressure in a subset of the population undergoing a lifestyle intervention [54]. The 
biological mechanism by which PFAS exposure may affect blood pressure is not well understood, but 
evidence in animals [55] and in vitro in human cell lines [56 57] suggests that PFAS exposure may 
increase oxidative stress, which may in turn lead to elevated blood pressure [58]. Though additional 
studies are needed, our results suggest that plasma concentrations of certain PFAS in pregnancy are 
associated with a shift towards a higher-risk profile across multiple distinct measures of 
anthropometry, blood pressure, and biomarkers in postpartum.  
Interestingly, we found protective associations between PFHxS and several biomarkers of 
metabolism. Specifically, higher plasma concentrations of PFHxS were statistically significantly 
associated with higher adiponectin and SHBG, and higher PFHxS was statistically significantly 
associated with smaller SS+TR skinfold thickness in models containing all PFAS. A few previous 
studies of other outcomes have reported protective effects of PFHxS, including inverse associations of 
PFHxS with low-density lipoprotein cholesterol levels [59] and risk of breast cancer [60 61]. In vitro, 
PFHxS and PFOA have similar affinity to human PPAR  ligand binding domain [62], so it is not 
clear why PFHxS might act in the opposite direction of other PFAS.  
Our biomarker results add to an inconsistent and largely cross-sectional previous literature 
that has reported positive, inverse, and null results for all six biomarkers investigated in this study. 
Our findings do align with some prior literature. For example, the significant positive association of 
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studies reported mixed findings [30-32]); similarly, the non-significantly positive association of 
EtFOSAA and HbA1c is broadly consistent with findings from two cross-sectional studies (though 
two other studies reported null or inverse findings [20 32 63 64]) and aligns with our findings that 
PFAS concentrations are associated with increased adiposity. Additionally, we reported statistically 
significant positive associations of EtFOSAA and MeFOSAA and IL-6; this is in line with a previous 
prospective study in pregnant and postpartum women that found a positive association with PFOS and 
PFOA and IL-6 [35]. IL-6 may be upregulated in response to higher oxidative stress [65] that may 
result from PFAS exposure [56 57]. However, in other cases our results conflicted with prior 
literature. For example, we reported null associations of PFAS and leptin, but prior prospective and 
cross-sectional studies have linked PFAS concentrations with higher leptin [20 29 30], and we 
expected to find a positive association given the positive associations we reported with PFAS and 
measures of adiposity. We also reported a statistically significant positive association of PFHxS and 
SHBG, and a statistically significant inverse association of EtFOSAA and SHBG; most previous 
studies of this association were restricted to men, and six of eight studies reported null findings (two 
studies, both in men, reported positive associations for PFOS and PFOA) [66-73]. Finally, we 
reported statistically significant inverse associations of MeFOSAA and CRP, but three cross-sectional 
studies (including one in pregnant women) have reported null associations of PFAS and CRP [31 34 
74]. Additional work is needed to understand the complex potential associations of PFAS and blood 
biomarkers.  
Pregnancy is a well-known sensitive window for fetal development, but few studies have 
tested pregnancy as a sensitive window for long-term maternal health. As an exception, some recent 
breast cancer research has identified pregnancy as a window of susceptibility for environmental 
exposures, likely because breast tissue develops and changes during pregnancy [75]. The maternal 
cardiovascular system also changes rapidly during pregnancy [76], and cardiometabolic health may be 
affected by environmental exposures similar to breast tissue. Indeed, our findings suggest that higher 
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after adjustment for pre-pregnancy risk factors such as BMI, supporting the idea of pregnancy as a 
sensitive window for maternal health.      
Our work is subject to limitations. Between pregnancy and three years postpartum, the cohort 
had substantial loss to follow-up; we corrected for potential selection bias due to this loss to follow up 
using IPCW. Breastfeeding may be an important predictor of postpartum cardiometabolic health; 
however, breastfeeding after the index pregnancy may lie on the causal pathway between PFAS and 
the outcomes of interest and therefore would be inappropriate to adjust for in multivariate models [77 
78]. However, we adjusted for history of breastfeeding. The effects of PFAS on cardiometabolic 
outcomes could be modified by kidney function; however, in our population of relatively young, 
healthy women, only 3.9% had inadequate kidney function based on a single measurement of 
estimated glomerular filtration rate calculated using the Cockroft-Gault formula [79 80], so we were 
not able to evaluate this possible effect modifier. We examined multiple correlated outcomes, but 
existing composite cardiovascular risk scores were not meaningful to summarize our findings because 
Project Viva is comprised of young, relatively healthy women. Additionally, we did not adjust our 
results for multiple testing, so individual statistically significant associations should be interpreted 
with caution. However, the pattern of results across multiple markers paints a clear picture of 
associations of higher concentrations of PFAS and worse cardiometabolic health. Finally, we report 
generally small effect sizes with wide confidence intervals. We cannot rule out false negatives due to 
lack of power to detect subtle effects; the direction of associations (including non-significant 
associations) is largely consistent with our hypotheses. The cohort was generally young and healthy at 
pregnancy; longer follow-up time may produce larger effects as participants age.  
Our study also had many strengths. We were able to follow a large cohort of participants from 
early pregnancy to three years postpartum, so our study was prospective and captured the sensitive 
window of pregnancy. Trained RAs collected outcome measurements without knowledge of 
participants’ PFAS concentrations; because these outcomes are not highly correlated, they each 
contribute to a broad picture of cardiometabolic risk. We also used biomonitoring (e.g., PFAS in 
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concentrations reported here are similar to those reported nationally in the same time frame [13], our 
findings may be generalizable to an American population with typical exposures. 
 
Conclusions 
In Project Viva, we found that pregnancy plasma concentrations of EtFOSAA, PFOS, and 
PFOA were associated with a shift towards a higher-risk profile at three years postpartum across 
several measures of anthropometry, blood pressure, and biomarkers of cardiometabolic health. Our 
results reinforce the status of pregnancy as a sensitive window for maternal health, though further 
research is needed to fully elucidate the mechanism connecting pregnancy PFAS concentrations and 
changes in postpartum health. Future research should evaluate postpartum maternal health effects of 
chemical exposures in pregnancy, using animal models and additional epidemiological cohort studies. 
Studies should additionally incorporate longer follow-up time to test duration of effects. Intervention 
studies during and before pregnancy that aim to reduce these exposures could also help elucidate 
causal pathways. If additional evidence supports our findings, incorporating PFAS exposure reduction 
strategies into clinical care for women planning pregnancy could improve maternal cardiometabolic 
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Age at enrollment  
Mean (SD) age (years) 32.7 (5.2) 
<25 years 58 (7.1) 
25 - <30 years 143 (17.6) 
30 - <35 years 324 (39.9) 
 35 years 287 (35.3) 
Year of enrollment  
1999 204 (25.1) 
2000 294 (36.2) 
2001 288 (35.5) 
2002 26 (3.2) 
Pre-pregnan y body mass index (BMI)  
Median (IQR) BMI (kg/m
2
) 23.7 (21.3, 27.3) 
<25.0 kg/m
2
 496 (61.1) 
25.0 - <30.0 kg/m
2
 194 (23.9) 
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White 577 (71.1) 
Black 103 (12.7) 
Other 132 (16.2) 
Parity  
0 353 (43.5) 
1 309 (38.1) 
>1 150 (18.5) 
Education  
< College graduate 252 (31.0) 
College graduate or more 560 (69.0) 
Married or cohabitating  
No 67 (8.2) 
Yes 745 (91.8) 
Smoking status  
Smoked during pregnancy 93 (11.5) 
Former 164 (20.3) 
Never 554 (68.3) 
Annual household income  
 $70,000/year  322 (39.6)  
>$70,000/year 490 (60.4) 
History of breastfeeding  
No 424 (52.3) 
Yes 388 (47.7) 
Gestational weight gain
2
   
Inadequate 98 (12.2) 
Adequate 232 (28.9) 
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1-year postpartum weight retention  
<5 kg 529 (86.6) 
 5 kg 82 (13.4) 
1
Calculated from all imputations. Ns are rounded to the nearest integer; values may not sum to 812. 
Gestational weight gain and postpartum weight retention are not imputed. 
2
According to Institute of Medicine (2009) guidelines 
3
Three participants have measurements of blood pressure and not anthropometry, and three participants 
have biomarkers measurements and not anthropometry. Otherwise the blood pressure and biomarker 
populations are subsets of the anthropometry population. Further study population details are provided in 
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Figure 1. Associations between PFAS plasma concentrations in pregnancy and anthropometry at 3 
years postpartum. Effect estimates are per doubling in each PFAS, based on parameter estimates from 
regression models (adjusted for age, pre-pregnancy BMI, marital status, race/ethnicity, education, 
income, smoking, and parity). Plotted values are listed in Supplemental Table S4 [44].  
 
Figure 2. Associations between PFAS plasma concentrations in pregnancy and blood pressure (BP) at 
3 years postpartum. Effect estimates are per doubling in each PFAS, based on parameter estimates 
from regression models (adjusted for age, pre-pregnancy BMI, marital status, race/ethnicity, 
education, income, smoking, and parity). Plotted values are listed in Supplemental Table S4 [44].  
 
Figure 3. Associations between PFAS plasma concentrations in pregnancy and anthropometry and 
blood pressure at 3 years postpartum. Effect estimates are percent change in each biomarker per 
doubling in each PFAS, based on parameter estimates from regression models (adjusted for age, pre-
pregnancy BMI, marital status, race/ethnicity, education, income, smoking, and parity). Plotted values 
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